Mergers & Acquisitions
Nov. 30, 2010
Drug-Making Partnerships Expected to Rise
In an environment where biotechnology firms need money and pharmaceutical companies need new drugs, partnerships between the two are bound to rise.
Daily Journal Staff Writer
Pharmaceutical companies desperate to fill product pipelines as patents near expiration remain slow to wed biotechnology firms with promising new drug candidates, despite increasing competition from overseas.
Dealmaking that partners multi-billion-dollar collaborators with biotechs in need of funds is poised for a global comeback as drugmakers and foreign investors look for new relationships. Still,...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In